Biopharma start-up fundraising more than doubled to $3.87bn in the second quarter versus the prior quarter, helped by initial public offerings, including the Actelion Pharmaceuticals Ltd. spinout Idorsia Pharmaceuticals Ltd.'s IPO in Switzerland totaling $1.23bn.
Strategic Transactions data also showed several alliances in the start-up world, but academia got in on the act too, including Harvard Medical School and Monash University
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?